Page 179 - 2020_02-Haematologica-web

HLA-matched unrelated or haploidentical donor
1-2020 from the Office of Naval Research. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the
Department of Defense, Health Resources and Services Administration or any other agency of the U.S. Government or Corporate Sponsor.
References
1. O'Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplan- tation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8(7):377-386.
2. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow trans- plantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophos- phamide. Biol Blood Marrow Transplant. 2008;14(6):641-650.
3. Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA- mismatched related bone marrow or unre- lated double umbilical cord blood grafts. Blood. 2011;118(2):282-288.
4. Kasamon YL, Bolanos-Meade J, Prince GT, et al. Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post- Transplantation Cyclophosphamide in Older Adults. J Clin Oncol. 2015;33(28):3152-3161.
5. Bashey A, Zhang MJ, McCurdy SR, et al. Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2017;35(26):3002-3009.
6. Ciurea SO, Zhang MJ, Bacigalupo AA, et al. Haploidentical transplant with posttrans- plant cyclophosphamide vs matched unre- lated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033-1040.
7. Versluis J, Labopin M, Ruggeri A, et al. Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. Blood Adv. 2017;1(7):477-485.
8. Santoro N, Labopin M, Giannotti F, et al. Unmanipulated haploidentical in compari- son with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a com- parative study on behalf of the ALWP of the EBMT. J Hematol Oncol. 2018;11(1):55.
9. Robinson TM, Fuchs EJ, Zhang MJ, et al. Related donor transplants: has posttrans- plantation cyclophosphamide nullified the detrimental effect of HLA mismatch? Blood Adv. 2018;2(11):1180-1186.
10. Alousi AM, Le-Rademacher J, Saliba RM, et al. Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? Blood. 2013; 121(13):2567-2573.
11. Kollman C, Spellman SR, Zhang MJ, et al. The effect of donor characteristics on sur- vival after unrelated donor transplantation for hematologic malignancy. Blood. 2016;127(2):260-267.
12. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
13. Flowers ME, Kansu E, Sullivan KM. Pathophysiology and treatment of graft- versus-host disease. Hematol Oncol Clin North Am. 1999;13(5):1091-1112, viii-ix.
14. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc. 1958;53(282):457-481.
15. Lin DY. Non-parametric inference for cumulative incidence functions in compet- ing risks studies. Stat Med. 1997;16(8):901- 910.
16. Cox DR. Regression Models and Life- Tables. J R Stat Soc Series B Stat Methodol. 1972;34(2):187-220.
17. Andersen PK, Klein JP, Zhang MJ. Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18(12):1489-1500.
18. Muffly L, Pasquini MC, Martens M, et al.
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130(9):1156-1164.
19. Pidala J, Lee SJ, Ahn KW, et al. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood. 2014;124(16):2596- 2606.
20. McCurdy SR, Zhang MJ, St Martin A, et al. Effect of donor characteristics on hap- loidentical transplantation with posttrans- plantation cyclophosphamide. Blood Adv. 2018;2(3):299-307.
21. Eapen M, Brazauskas R, Hemmer M, et al. Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. Blood Adv. 2018;2(16):2095-2103.
22. Scott BL, Pasquini MC, Logan BR, et al. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2017;35(11):1154-1161.
23. Sun CL, Francisco L, Baker KS, Weisdorf DJ, Forman SJ, Bhatia S. Adverse psycho- logical outcomes in long-term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS). Blood. 2011;118(17):4723- 4731.
24. Sun CL, Kersey JH, Francisco L, et al. Burden of morbidity in 10+ year survivors of hematopoietic cell transplantation: report from the bone marrow transplanta- tion survivor study. Biol Blood Marrow Transplant. 2013;19(7):1073-1080.
25. Lee SJ, Logan B, Westervelt P, et al. Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial. JAMA Oncol. 2016;2(12): 1583-1589.
haematologica | 2020; 105(2)
413